Logo image of MRT

MARTI TECHNOLOGIES INC (MRT) Stock Fundamental Analysis

NYSEARCA:MRT - NYSE Arca - US5731341039 - Common Stock - Currency: USD

3.31  +0.17 (+5.41%)

Fundamental Rating

1

MRT gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 41 industry peers in the Ground Transportation industry. Both the profitability and financial health of MRT have multiple concerns. MRT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MRT has reported negative net income.
In the past year MRT has reported a negative cash flow from operations.
MRT had negative earnings in each of the past 5 years.
In the past 5 years MRT always reported negative operating cash flow.
MRT Yearly Net Income VS EBIT VS OCF VS FCFMRT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of MRT (-183.73%) is worse than 90.24% of its industry peers.
Industry RankSector Rank
ROA -183.73%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MRT Yearly ROA, ROE, ROICMRT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -0.5 -1 -1.5

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MRT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRT Yearly Profit, Operating, Gross MarginsMRT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

MRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
MRT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MRT Yearly Shares OutstandingMRT Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 10M 20M 30M 40M
MRT Yearly Total Debt VS Total AssetsMRT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 50M 100M

2.2 Solvency

Based on the Altman-Z score of -4.97, we must say that MRT is in the distress zone and has some risk of bankruptcy.
MRT has a worse Altman-Z score (-4.97) than 87.80% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.97
ROIC/WACCN/A
WACC9.14%
MRT Yearly LT Debt VS Equity VS FCFMRT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 1.47 indicates that MRT should not have too much problems paying its short term obligations.
MRT has a Current ratio of 1.47. This is in the better half of the industry: MRT outperforms 75.61% of its industry peers.
A Quick Ratio of 1.32 indicates that MRT should not have too much problems paying its short term obligations.
The Quick ratio of MRT (1.32) is better than 70.73% of its industry peers.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.32
MRT Yearly Current Assets VS Current LiabilitesMRT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2M 4M 6M 8M 10M

More info and screens

3

3. Growth

3.1 Past

MRT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -74.65%.
Looking at the last year, MRT shows a decrease in Revenue. The Revenue has decreased by -6.84% in the last year.
EPS 1Y (TTM)-74.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.65%
Revenue 1Y (TTM)-6.84%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-6.84%

3.2 Future

The Earnings Per Share is expected to grow by 45.38% on average over the next years. This is a very strong growth
Based on estimates for the next years, MRT will show a very strong growth in Revenue. The Revenue will grow by 97.81% on average per year.
EPS Next Y51.77%
EPS Next 2Y45.38%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year103.32%
Revenue Next 2Y97.81%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

MRT Yearly Revenue VS EstimatesMRT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 20M 40M 60M
MRT Yearly EPS VS EstimatesMRT Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 0 -0.2 -0.4 -0.6 -0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRT Price Earnings VS Forward Price EarningsMRT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRT Per share dataMRT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as MRT's earnings are expected to grow with 45.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.38%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARTI TECHNOLOGIES INC

NYSEARCA:MRT (5/8/2025, 6:30:00 PM)

3.31

+0.17 (+5.41%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupTransportation
GICS IndustryGround Transportation
Earnings (Last)04-29 2025-04-29
Earnings (Next)N/A N/A
Inst Owners17.8%
Inst Owner Change0%
Ins Owners27.53%
Ins Owner Change0%
Market Cap252.35M
Analysts76.67
Price Target5.29 (59.82%)
Short Float %0.27%
Short Ratio1.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)66.67%
PT rev (3m)66.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-6.82%
EPS NY rev (3m)-6.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.61%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.52
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.17
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0.24
BVpS-0.43
TBVpS-0.43
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -183.73%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.95%
Cap/Sales 5.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.32
Altman-Z -4.97
F-Score4
WACC9.14%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-74.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-74.65%
EPS Next Y51.77%
EPS Next 2Y45.38%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-6.84%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-6.84%
Revenue Next Year103.32%
Revenue Next 2Y97.81%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-119.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year46.25%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-68.69%
OCF growth 3YN/A
OCF growth 5YN/A